{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:43Z","timestamp":1790707243150,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Program of Guangzhou","award":["202102080498"],"award-info":[{"award-number":["202102080498"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05691-2","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T03:01:55Z","timestamp":1709866915000},"page":"3207-3217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-8939","authenticated-orcid":false,"given":"Wenjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"5691_CR1","doi-asserted-by":"publisher","first-page":"105695","DOI":"10.1016\/j.phrs.2021.105695","volume":"170","author":"MG Shetty","year":"2021","unstructured":"Shetty MG, Pai P, Deaver RE et al (2021) Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res 170:105695","journal-title":"Pharmacol Res"},{"key":"5691_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","volume":"23","author":"M Shvedunova","year":"2022","unstructured":"Shvedunova M, Akhtar A (2022) Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol 23:329\u2013349","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5691_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","volume":"42","author":"R Shah","year":"2019","unstructured":"Shah R (2019) Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf 42:235\u2013245","journal-title":"Drug Saf"},{"key":"5691_CR4","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1111\/bcp.14889","volume":"87","author":"A Bondarev","year":"2021","unstructured":"Bondarev A, Attwood M, Jonsson J et al (2021) Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol 87:4577\u20134597","journal-title":"Br J Clin Pharmacol"},{"key":"5691_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3324\/haematol.2009.009217","volume":"94","author":"E Schaefer","year":"2009","unstructured":"Schaefer E, Loaiza-Bonilla A, Juckett M et al (2009) A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 94:1375\u20131382","journal-title":"Haematologica"},{"key":"5691_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/cncr.29229","volume":"121","author":"JD Hainsworth","year":"2015","unstructured":"Hainsworth JD, Daugaard G, Lesimple T et al (2015) Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial. Cancer 121:1654\u20131661","journal-title":"Cancer"},{"key":"5691_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VTM, Yoon S-S et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15:1195\u20131206","journal-title":"Lancet Oncol"},{"key":"5691_CR8","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:1766\u20131771","journal-title":"Ann Oncol"},{"key":"5691_CR9","doi-asserted-by":"publisher","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","volume":"50","author":"Y-D Yan","year":"2022","unstructured":"Yan Y-D, Zhao Y, Zhang C et al (2022) Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine 50:101535","journal-title":"EClinicalMedicine"},{"key":"5691_CR10","doi-asserted-by":"publisher","first-page":"1266890","DOI":"10.3389\/fphar.2023.1266890","volume":"14","author":"T Yuan","year":"2023","unstructured":"Yuan T, Li F, Hou Y et al (2023) Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study. Front Pharmacol 14:1266890","journal-title":"Front Pharmacol"},{"key":"5691_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","volume":"89","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Gamble J-M (2023) Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol 89:431\u2013439","journal-title":"Br J Clin Pharmacol"},{"key":"5691_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F et al (2020) Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol 15:449\u2013466","journal-title":"Target Oncol"},{"key":"5691_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark B, Holmberg L, Garmo H et al (2014) Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol 70:627\u2013635","journal-title":"Eur J Clin Pharmacol"},{"key":"5691_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I et al (2021) Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol 28:983\u2013989","journal-title":"Eur J Prev Cardiol"},{"key":"5691_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","volume":"162","author":"L Gaucher","year":"2023","unstructured":"Gaucher L, Sabatier P, Katsahian S et al (2023) Pharmacovigilance studies without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures. J Clin Epidemiol 162:127\u2013134","journal-title":"J Clin Epidemiol"},{"key":"5691_CR16","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S et al (2021) Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 137:2161\u20132170","journal-title":"Blood"},{"key":"5691_CR17","doi-asserted-by":"publisher","first-page":"732727","DOI":"10.3389\/fmed.2021.732727","volume":"8","author":"J Du","year":"2021","unstructured":"Du J, Han X, Lin S et al (2021) Efficacy and treatment-related adverse events of romidepsin in PTCL clinical studies: a systematic review and meta-analysis. Front Med 8:732727","journal-title":"Front Med"},{"key":"5691_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.clml.2018.05.007","volume":"18","author":"JD Cavenagh","year":"2018","unstructured":"Cavenagh JD, Popat R (2018) Optimal management of histone deacetylase inhibitor-related adverse events in patients with multiple myeloma: a focus on panobinostat. Clin Lymphoma Myeloma Leuk 18:501\u2013507","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5691_CR19","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T et al (2015) Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492\u20132499","journal-title":"J Clin Oncol"},{"key":"5691_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K et al (2023) Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica 108:811\u2013821","journal-title":"Haematologica"},{"key":"5691_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C et al (2016) The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood 128:138\u2013140","journal-title":"Blood"},{"key":"5691_CR22","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1161\/CIRCRESAHA.121.318223","volume":"128","author":"VS Hahn","year":"2021","unstructured":"Hahn VS, Zhang KW, Sun L et al (2021) Heart failure with targeted cancer therapies: mechanisms and cardioprotection. Circ Res 128:1576\u20131593","journal-title":"Circ Res"},{"key":"5691_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41569-019-0235-9","volume":"17","author":"P Li","year":"2020","unstructured":"Li P, Ge J, Li H (2020) Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol 17:96\u2013115","journal-title":"Nat Rev Cardiol"},{"key":"5691_CR24","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1080\/10428194.2022.2123222","volume":"63","author":"A Zduniak","year":"2022","unstructured":"Zduniak A, L\u00e9v\u00eaque E, Perdrix A et al (2022) Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy. Leuk Lymphoma 63:3340\u20133350","journal-title":"Leuk Lymphoma"},{"key":"5691_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12890-022-01832-3","volume":"22","author":"X Peng","year":"2022","unstructured":"Peng X, Huang M, Zhao W et al (2022) RAGE mediates airway inflammation via the HDAC1 pathway in a toluene diisocyanate-induced murine asthma model. BMC Pulm Med 22:61","journal-title":"BMC Pulm Med"},{"key":"5691_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12272-017-0998-7","volume":"41","author":"P Chun","year":"2018","unstructured":"Chun P (2018) Therapeutic effects of histone deacetylase inhibitors on kidney disease. Arch Pharmacal Res 41:162\u2013183","journal-title":"Arch Pharmacal Res"},{"key":"5691_CR27","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/hep.22486","volume":"48","author":"K Miura","year":"2008","unstructured":"Miura K, Taura K, Kodama Y et al (2008) Hepatitis C virus-induced oxidative stress suppresses hepcidin express ion through increased histone deacetylase activity. Hepatology (Baltimore, MD) 48:1420\u20131429","journal-title":"Hepatology (Baltimore, MD)"},{"key":"5691_CR28","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A et al (2023) Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System ( FAERS) database. EClinicalMedicine 59:101967","journal-title":"EClinicalMedicine"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05691-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:05:43Z","timestamp":1722060343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05691-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5691"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05691-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval and written consent were needed for the secondary analysis of public data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}